Wellington Management Group LLP Has $216.28 Million Holdings in Sanofi (NASDAQ:SNY)

Wellington Management Group LLP trimmed its position in shares of Sanofi (NASDAQ:SNY) by 3.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,484,318 shares of the company’s stock after selling 166,016 shares during the period. Wellington Management Group LLP owned 0.18% of Sanofi worth $216,279,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SNY. Charles Schwab Investment Management Inc. increased its stake in shares of Sanofi by 31.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock worth $8,040,000 after purchasing an additional 33,105 shares during the last quarter. Arkadios Wealth Advisors increased its position in Sanofi by 19.0% during the fourth quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock worth $227,000 after buying an additional 751 shares during the last quarter. Geode Capital Management LLC increased its position in Sanofi by 7.1% during the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock worth $14,681,000 after buying an additional 16,780 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Sanofi by 20.9% in the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after buying an additional 399,301 shares during the period. Finally, Kentucky Trust Co acquired a new stake in shares of Sanofi in the fourth quarter valued at approximately $436,000. 14.04% of the stock is owned by institutional investors.

Sanofi Trading Down 0.7 %

Shares of Sanofi stock opened at $53.95 on Thursday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The firm has a 50-day moving average of $55.33 and a 200-day moving average of $52.74. Sanofi has a 52-week low of $45.22 and a 52-week high of $60.12. The stock has a market cap of $136.92 billion, a PE ratio of 21.67, a PEG ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, sell-side analysts forecast that Sanofi will post 4.36 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on SNY. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. The Goldman Sachs Group began coverage on shares of Sanofi in a research report on Friday, March 21st. They issued a “neutral” rating and a $65.00 price objective on the stock. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $62.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.